What a Clinical Study Report Must Contain: A Practical Guide to ICH E3

What a clinical study report is and why its structure matters

An ICH E3 clinical study report is a comprehensive document that integrates clinical and statistical descriptions, presentations, and analyses from a single clinical trial, following the standards set by the International Conference on Harmonisation (ICH) E3 guideline. Producing an ICH E3 clinical study report ensures that the data and findings from a study are presented in a format acceptable to regulatory authorities in the European Union, Japan, and the USA, streamlining the review and approval process for new therapies¹.

The clinical study report structure defined by ICH E3 is designed to be clear, thorough, and unambiguous, allowing reviewers to understand exactly how the study was planned, conducted, and analyzed. This structure includes sections such as the title page, synopsis, table of contents, list of abbreviations, ethics, investigator information, study objectives, investigational plan, and detailed results, among others¹. Each section serves a specific purpose, such as documenting ethical oversight, providing key study design details, or presenting efficacy and safety data in a way that supports regulatory decision-making.

Adhering to the ICH E3 clinical study report structure is critical because it enables consistent reporting across studies and sponsors, facilitates comparison and replication of results, and ensures that all information required for regulatory review is included. The integrated nature of the report means that clinical and statistical content is combined, rather than presented as separate documents, which helps prevent ambiguity and ensures that the rationale and outcomes of the study are fully transparent¹.

The core sections of a CSR under ICH E3

The ICH E3 clinical study report is structured to ensure clarity, completeness, and regulatory compliance. Each section serves a distinct purpose in documenting the study’s conduct and findings, making the clinical study report structure essential for both regulatory review and future reference. The main body of the CSR begins with the title page, which details the study title, investigational product, sponsor, protocol identification, and key dates. This is followed by a synopsis that summarises the study’s objectives, methodology, results, and conclusions in a concise format, typically limited to three pages and including key numerical data to illustrate results rather than relying solely on text or p-values¹.

The table of contents provides a roadmap to all sections, summary tables, figures, and appendices. A list of abbreviations and definitions clarifies specialised terms used throughout the report. The ethics section documents the involvement of independent ethics committees or institutional review boards, ethical conduct, and details of patient consent procedures. Information about investigators and study administration is included to identify all key personnel and their qualifications¹.

Subsequent sections cover the introduction, study objectives, and a detailed investigational plan, which describes the study design, control groups, and patient selection criteria. The report then presents demographic data, efficacy results, and safety data using summary tables and figures. The reference list cites literature relevant to the study, and the appendices provide supporting documents such as the protocol, case report forms, investigator lists, randomisation schemes, audit certificates, and detailed patient data listings. For those involved in CSR writing, following this structure is critical to meet regulatory expectations and facilitate transparent reporting¹.

Describing study design, endpoints and patient populations

In an ICH E3 clinical study report, the description of study design, endpoints, and patient populations is central to ensuring transparency and reproducibility. The clinical study report structure requires a clear account of the overall study design, including whether the trial was randomised, blinded, parallel, or cross-over, and the rationale for these choices. This section should also detail the control groups used, such as placebo or active comparators, and explain why these were selected in the context of the investigational product and research objectives ¹.

Endpoints must be explicitly defined, distinguishing between primary and secondary endpoints. The report should specify the criteria for evaluating efficacy and safety, including the timing and methods of assessment. This information is vital for regulatory reviewers to understand how outcomes were measured and to assess the validity of the results ¹.

The patient population section should outline the inclusion and exclusion criteria, providing a profile of the study participants. Demographic and baseline characteristics, such as age, sex, diagnosis, and relevant medical history, are typically summarised in tables or figures. The report should also document the number of patients planned versus those actually enrolled and analysed, and describe any protocol deviations or reasons for patient exclusion from efficacy analyses. Listings of individual patient data, including those excluded from analyses, are included in the appendices to support transparency and allow for independent review ¹.

For those involved in CSR writing, it is important to ensure that all analyses, tables, and figures clearly identify the patient sets from which data were generated. This level of detail supports regulatory scrutiny and helps ensure that the study’s findings can be independently verified if required ¹.

Presenting efficacy results

In the ICH E3 clinical study report, presenting efficacy results requires a clear, structured approach that integrates both clinical and statistical findings. The guideline specifies that efficacy data should be summarised using tables and figures, which may be incorporated into the main text or appended at the end of the report, depending on the clinical study report structure and regulatory requirements. Each analysis must indicate the specific patient set it is derived from, such as the intention-to-treat or per-protocol population, to ensure transparency and reproducibility of results ¹.

The efficacy section should detail the outcomes for all primary and secondary endpoints, referencing the statistical methods described earlier in the report. Numerical results, such as response rates or changes from baseline, are typically presented alongside confidence intervals and p-values to support interpretation. Where appropriate, subgroup analyses and sensitivity analyses are included to address variability within the patient population and to test the robustness of the findings ¹.

According to ICH E3, any patients or observations excluded from the efficacy analysis must be listed and justified in the appendices, with cross-references in the main efficacy results section. This level of documentation supports regulatory review and allows for independent verification of the analyses. The guideline also recommends that all tables and figures be clearly labelled, with legends that specify the analysis set and statistical approach used ¹.

Reporting safety: adverse events and laboratory findings

Within the ICH E3 clinical study report, safety reporting is a core requirement that ensures regulatory authorities receive a transparent account of all adverse events and relevant laboratory findings associated with the investigational product. The clinical study report structure, as outlined in the guideline, specifies dedicated sections for summarising and displaying safety data, including adverse event tables, listings of deaths and other serious or significant adverse events, and narratives for cases of particular importance ¹.

Adverse events are typically presented in summary tables, with further breakdowns by severity, relationship to the study drug, and outcome. The CSR writing process must also include detailed listings for deaths and other serious events, as well as narratives for individual cases where additional context is warranted. This approach supports regulatory review by providing both aggregate data and patient-level detail, enabling assessment of potential safety signals ¹.

Laboratory findings are reported alongside adverse events, with abnormal values listed for each patient when required. The guideline allows for the inclusion of comprehensive laboratory data in appendices, which can be referenced in the main text to avoid overwhelming the report with excessive detail. This ensures that safety data are accessible for in-depth analysis while maintaining clarity in the main body of the report ¹.

In practice, the integration of safety data with efficacy and demographic information within the ICH E3 clinical study report supports a holistic evaluation of the investigational product’s benefit-risk profile. The structure also facilitates the identification of trends or unexpected findings that may warrant further investigation or regulatory attention ¹.

Limits of the guideline and what to check before drafting

While the ICH E3 clinical study report guideline provides a comprehensive framework for clinical study report structure, it is not exhaustive. The guideline is designed to be broadly applicable across different types of studies and regulatory regions, but it recognises that additional, region-specific requirements may apply. For example, regulatory authorities may request supplementary modules or appendices tailored to their own review processes, which are not detailed in the core guideline itself¹.

Before drafting, it is essential to review the latest regulatory expectations for the target submission region. This includes verifying whether local authorities require specific formats for appendices, additional data listings, or particular documentation of statistical methods and quality assurance procedures. The guideline also allows for flexibility in the level of detail, especially for studies such as clinical pharmacology trials, where a less detailed report may be appropriate depending on the study’s nature and importance¹.

Authors should check that all critical design features, methods, and analyses are described with enough clarity to avoid ambiguity and to enable replication of results if needed. It is also important to ensure that all tables, figures, and analyses clearly identify the patient populations from which data were generated. Finally, confirm that all required appendices—such as protocols, case report forms, investigator CVs, and audit certificates—are available and finalised, as some may only need to be submitted upon request by regulatory authorities¹.